Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

December 21, 2023

https://www.globenewswire.com/news-release/2023/12/21/2799963/25416/en/Vaxart-Announces-Last-Subject-Dosed-in-Phase-1-Trial-of-Its-Norovirus-Vaccine-Candidate-in-Lactating-Mothers.html

On track to report topline data by the end of 2024

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq:VXRT) today announced that it has completed enrollment and dosing in the Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate focused on lactating mothers.

Read more at globenewswire.com

Related news for (VXRT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.